Light Therapy in Cardiopulmonary Bypass Surgery

Status Withdrawn

Clinical Trial Summary

The goal of this study is to determine whether or not exposure to blue spectrum light reduces acute kidney injury and systemic inflammation in subjects undergoing cardiopulmonary bypass. Subjects scheduled to undergo cardiopulmonary bypass surgery will be exposed to either bright (1000 lux) blue spectrum (480nm) light or to ambient, white fluorescent light for a 24 hour photoperiod the day prior to surgery and for a 24 hour photoperiod in the immediate postoperative period.

Clinical Trial Description

Light modifies the biology and physiology of mammals, including humans. The cellular biology of both the immune system, as well as, the cells comprising tissues and organs (e.g., kidney, liver) are under the regulation of light and exhibit circadian rhythms. Studies show that the severity of organ injury varies with the time of the day, the duration of the day, and the season. This variation is due to the biology of circadian rhythms, and light is the principle environmental cue entraining circadian biology. More recent data suggest that modulating the spectrum of light to which an organism is exposed may therapeutically modulate the cellular response to stress or injury. Specifically, exposure to a short (24 hour) photoperiod of high illuminance, blue spectrum light attenuated liver and kidney injury when animals were subjected to ischemia/reperfusion (I/R), a model in which the blood flow to an organ is temporarily reduced and then restored. A predominant cause of organ injury in this model is the misdirected and exacerbated inflammation of a type of immune cell called the neutrophil. However, blue light inhibited neutrophil infiltration into the ischemic kidney and liver, and thereby reduced inflammation and neutrophil-mediated organ injury. Cardiopulmonary bypass (CPB) surgery is an operation characterized by excessive inflammation and a high risk of organ injury, particularly acute kidney injury (AKI). Thus, we hypothesize that exposure to blue light, by comparison to standard environmental, white fluorescent light, will reduce inflammation, organ injury and improve the outcome of patients undergoing CPB. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02928887
Study type	Interventional
Source	University of Pittsburgh
Contact
Status	Withdrawn
Phase	N/A
Start date	September 1, 2020
Completion date	June 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03995979` - Inflammation and Protein Restriction	N/A
Completed	`NCT03255187` - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution	N/A
Completed	`NCT04507867` - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III	N/A
Completed	`NCT03577223` - Egg Effects on the Immunomodulatory Properties of HDL	N/A
Completed	`NCT04383561` - Relationship Between LRG and Periodontal Disease	N/A
Active, not recruiting	`NCT03622632` - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Completed	`NCT06216015` - Exercise Training and Kidney Transplantation	N/A
Completed	`NCT04856748` - Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
Completed	`NCT05529693` - Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population	N/A
Recruiting	`NCT05415397` - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs	Phase 3
Recruiting	`NCT05670301` - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases	N/A
Recruiting	`NCT04543877` - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study	Early Phase 1
Recruiting	`NCT05775731` - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Completed	`NCT03859934` - Metabolic Effects of Melatonin Treatment	Phase 1
Completed	`NCT03429920` - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors	N/A
Completed	`NCT06065241` - Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals.	N/A
Completed	`NCT05864352` - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Completed	`NCT03318731` - Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males	N/A
Not yet recruiting	`NCT06134076` - Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota	N/A
Not yet recruiting	`NCT05910489` - Micro and Nanoplastics in Greenhouse Workers: Biomarkers of Exposure and Effect

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.